Pacific Biosciences of California, INC Form 4 insider transactions

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

James R. Gibson II, a Pacific Biosciences executive, was granted 2,000,000 stock options and 1,000,000 restricted stock units (RSUs) on March 31, 2025.

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, reports the acquisition of stock and options, as well as the disposal of stock, on March 19, 2025.

Mark Van Oene, Chief Operating Officer of Pacific Biosciences, reports acquisition of stock options and restricted stock units.

Christian O. Henry, CEO of Pacific Biosciences, reports acquisition of shares and stock options.

Pacific Biosciences CEO Christian O. Henry sold 12,497 shares of common stock on March 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Mark Van Oene, Chief Operating Officer of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Mark Van Oene, Chief Operating Officer of Pacific Biosciences, sold 100,773 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Christian Henry, CEO of Pacific Biosciences, sold 259,909 shares of common stock on February 18, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Christopher M. Smith joins Pacific Biosciences' Board of Directors, receiving stock and options as part of his compensation.

Mark Van Oene, Chief Operating Officer of Pacific Biosciences, sold 34,405 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Susan G. Kim, CFO of Pacific Biosciences, sold 19,782 shares of common stock on September 30, 2024, to cover tax withholding obligations related to vesting restricted stock units.

CEO Christian Henry sold 98,907 shares of Pacific Biosciences stock at an average price of $1.746 to cover tax withholding obligations related to vesting restricted stock units.

Jeff Eidel, Chief Commercial Officer of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Mark Van Oene, Chief Operating Officer of Pacific Biosciences, sold 38,011 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Director Hannah Valantine reported the acquisition of stock options and restricted stock units in Pacific Biosciences of California, Inc.

Director Lucy Shapiro acquired shares and options in Pacific Biosciences of California, Inc. on June 18, 2024.

Director Kathy Ordonez reports acquiring 22,821 shares of Pacific Biosciences common stock and disposing of 403,037 shares.

Director Marshall Mohr reports acquiring and disposing of Pacific Biosciences shares, including stock options and restricted stock units.

Director John F. Milligan reports receiving stock and option awards from Pacific Biosciences.

Director David W. Meline acquired shares and options in Pacific Biosciences of California, Inc. on June 18, 2024.

Director Randall S. Livingston reports acquisition of shares and options in Pacific Biosciences of California, Inc.

Director William W. Ericson reports acquisition of Pacific Biosciences shares and stock options, along with disposal of shares, in a recent SEC filing.

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold 5,275 shares of common stock on May 20, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Kathy Ordonez exercised stock options in Pacific Biosciences, acquiring and disposing of shares on March 15, 2024.

Director David W. Meline purchased 40,000 shares of Pacific Biosciences at an average price of $4.404 per share on March 6, 2024.

Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Mark Van Oene, COO of Pacific Biosciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.